TLSI

Business Context and Reporting Period

Company: Trisalus Life Sciences, Inc. (TLSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: Trisalus is an oncology-focused medical technology company developing Pressure Enabled Drug Delivery (PEDD) systems (TriNav) and the investigational immunotherapeutic nelitolimod. The company operates as a single reporting segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 42.0% to $9.2 million, driven by a $2.7 million increase in TriNav sales.
• Operating Expenses:
  • R&D: Decreased 43.6% to $3.3 million due to reduced clinical trial expenses for nelitolimod and lower headcount costs.
  • Sales & Marketing: Remained flat at $6.7 million; increased headcount costs were offset by reduced consultant usage.
  • G&A: Increased 7.4% to $5.0 million, primarily due to timing of audit and filing expenses.
• Interest Expense: Increased significantly to $1.2 million (from $3k) due to the utilization of the OrbiMed Credit Agreement.
• Debt Financing: The company drew a $10.0 million First Delayed Draw Term Loan in February 2025 after meeting revenue targets. Total long-term debt increased to $31.7 million.
• Non-Cash Items: The company recorded losses of $0.8 million related to the change in fair value of SEPA/warrant/revenue base redemption liabilities and $0.8 million for the contingent earnout liability.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional financing. Existing cash is deemed insufficient to fund projected liquidity requirements.
• Recent Capital Raises (Post-Period):
  • Private Placement: Closed May 2, 2025, raising approximately $22.0 million gross proceeds from the sale of 5.5 million shares at $4.00/share.
  • Debt Amendments: Received waivers for prior default events related to Series A Preferred Stock conversions and extended deadlines for audited financial statements.
• Reimbursement Status: TriNav received a second permanent HCPCS code (C8004) effective April 1, 2025, providing reimbursement clarity for mapping procedures.
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including insufficient trained resources, inadequate controls over patent costs, R&D accruals, and complex financial instruments (SEPA, Warrants, OrbiMed debt).
• Preferred Stock: Series A Convertible Preferred Stock conversion price was reset to $5.277 in February 2025, triggering conversions of 365,000 shares.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $22.0 million private placement proceeds combined with existing cash to cover operating losses and debt service obligations for the next 12 months.
• Debt Covenants: Review the OrbiMed Credit Agreement terms, specifically the "Product Revenue Base" thresholds required to avoid mandatory principal repayment and the impact of PIK (Payment-in-Kind) interest on debt balance.
• Reimbursement Stability: Monitor the adoption and reimbursement rates of the new HCPCS code C8004 and the impact on TriNav gross margins.
• Internal Control Remediation: Assess the progress of the remediation plan for material weaknesses in financial reporting, particularly regarding complex derivative valuations and accruals.
• Dilution Impact: Evaluate the dilutive effect of the recent private placement, outstanding warrants (SPAC and OrbiMed), and the potential conversion of Series A Preferred Stock.